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Since the introduction of extracorporeal membrane oxygenation (ECMO), more neonates
and children with cardiorespiratory failure survive. Interest has therefore shifted from
reduction of mortality toward evaluation of long-term outcomes and prevention
of morbidity. This review addresses the changes in ECMO population and the
ECMO-treatment that may affect long-term outcomes, the diagnostic modalities to
evaluate neurological morbidities and their contributions to prognostication of long-term
outcomes. Most follow-up data have only become available from observational follow-up
programs in neonatal ECMO-survivors. The main topics are discussed in this review.
Recommendations for long-term follow up depend on the presence of neurological
comorbidity, the nature and extent of the underlying disease, and the indication
for ECMO. Follow up should preferably be offered as standard of care, and in an
interdisciplinary, structured and standardized way. This permits evaluation of outcome
data and effect of interventions. We propose a standardized approach and recommend
that multiple domains should be evaluated during long-term follow up of neonates and
children who needed extracorporeal life support.
Keywords: extracorporeal membrane oxygenation, long-term outcomes, neurodevelopment, neuromonitoring,
follow-up
INTRODUCTION
Since the Extracorporeal Life Support Organization (ELSO) registry was launched in 1989, data of
more than 35,000 neonates and 20,000 children treated with extracorporeal membrane oxygenation
(ECMO) have been registered (1). Neonates were treated with ECMOmainly for respiratory failure;
older children more frequently for cardio-pulmonary failure (1).
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The indications and starting criteria for ECMO in neonates
are well defined. There is no evidence based criteria for
older children, likely due to the diverse etiology of the
cardiopulmonary failure in this age group (2, 3). As cumulative
experience with ECMO has increased, more and more complex
patients with co-morbidities, who previously would not have
qualified, are being referred for ECMO support (4). There is
evidence for ECMO as a treatment modality for respiratory
failure in neonates (5) and adults (6), but such evidence is
lacking for the pediatric age range. Randomized pediatric trials
addressing this issue have not been published. Uniform criteria,
such as the oxygenation index in neonates and the Murray
score of uncompensated hypercapnia with pH < 7.20 in adults,
are not available for the pediatric age range. Recently, Barbaro
and coworkers reported that in-hospital mortality and 90-day
ventilator-free, hospital-free and PICU-free days did not differ
between ECMO-supported children and non-ECMO supported
controls in the RESTORE (Randomized Evaluation of Sedation
Titration for Respiratory failure) clinical trial (7). The analysis
was based on individual case matching and propensity score
matching (7). A randomized controlled trial evaluating the real
benefit of pediatric ECMO is still relevant, However, based on
the study of Barbaro and coworkers (7), Carpenter and Kinsella
calculated that more than 1,200 children per group should be
included to show a significant difference in the mortality rate
(8). The currently available guidelines for pediatric ECMO on
the ELSO website clearly state that specific cut-offs at which
ECMO should be offered or withheld have not been firmly
established and therefore should be considered on a case-by-
case basis. Important absolute contraindications include lethal
chromosomal disorders and severe neurological compromise (3).
Of the ELSO-registered neonates, 75% were treated with
ECMO for severe respiratory failure and overall survival to
transfer or discharge in this group was 72% (1). Thus, seeing that
an increasing number of critically ill neonates—with a high risk
of mortality in the pre-ECMO era—survive, attention should be
directed to long-term morbidity.
The long-term outcome of ECMO patients is very diverse
due to the variety in underlying disease and additional
comorbidities (9). Most follow-up studies in neonates and
children who survived ECMO treatment have been cross-
sectional, monodisciplinary, and in small study populations.
The past few years have seen a shift toward long-term
multidisciplinary evaluations, mainly following neonatal ECMO.
This review addresses both medical and neurodevelopmental
outcomes after ECMO-treatment, as well as changes in ECMO
programs that might potentially influence long-term outcomes.
Recommendations will be made for follow up of these children
beyond infancy and childhood.
CHANGES IN ECMO PROGRAMS THAT
MIGHT AFFECT LONG-TERM OUTCOMES
ECMO programs worldwide have been subject to several changes
the last two decades. We distinguish two types of changes: First,
changes in indications that may lead to a different population
of survivors; and second, changes in techniques, devices and
medical management that may affect outcomes.
Changes in Indications
Historically, many ECMO programs first focused on newborns
with severe respiratory failure due to meconium aspiration
syndrome (MAS), pneumonia/sepsis, congenital diaphragmatic
hernia (CDH) or idiopathic persisting pulmonary hypertension
of the newborn (PPHN). It appeared, however, that there was
a high risk of complications and mortality for ECMO runs
longer than 2–3 weeks (10). The indications in the newborn
population have significantly changed since the introduction
of high-frequency oscillatory ventilation, inhaled nitric oxide,
intravenous sildenafil, and surfactant washout for MAS, among
other modalities. Moreover, better obstetric care has lowered
the prevalence of MAS and the resultant decrease in the rate of
ECMO utilization in this population (11).
Indications for ECMO support in older children have
broadened to include primary cardiac failure, post cardiac
surgery patients and primary respiratory failure. Especially since
the 2009 influenza H1N1 pandemic, ECMO is being applied
more often and more in the older pediatric and adult populations
with conditions that may require longer ECMO runs as a bridge
to either recovery or transplantation (12). Despite the decline
in survival with longer duration of ECMO, prolonged ECMO
support in children appears reasonable unless multiorgan failure
develops (4).
This change in policies implies that the previously excluded
neonates and children with higher disease severity due to
underlying disease ansd pre-existant morbidity can be treated
with ECMO with a chance of survival.
Traditionally, cardiopulmonary resuscitation (CPR) was a
contraindication for ECMO. A decade ago, however, ECMO
was introduced as a rescue therapy during CPR (ECPR),
and this resulted in higher survival rates and improved
neurologic outcomes in comparison with standard CPR.
Since then ECPR has been integrated in the Guidelines for
Cardiopulmonary Resuscitation and Emergency Cardiovascular
Care (13–15). Prospective randomized controlled studies that
compare outcomes from ECPR with conventional CPR have
not yet been reported; outcomes of ECPR have been described
in observational studies and meta-analyses only. In the 2018
January report from the ELSO registry, survival to discharge
following ECPR was 29% in 4,745 adults, 42% in 3,881 children
and 40% in 1,694 neonates (1).
In adults treated with ECPR, survivors were discharged with
favorable neurological outcome (Cerebral Performance Category
1 or 2) (16). The total arrest time proved to be themost important
predictor for good neurological outcome and recovery of heart
function in adult survivors of ECPR (17). In a study in children
receiving ECPR, the Pediatric Cerebral Performance Category
was 1 or 2 in 75% of survivors. Furthermore, there was a 52%
reduction risk of CNS injury compared with the immediate pre-
ECPR era (18). tThe clinical relevance of this score is limited,
however, which will be discussed later. Studies evaluating long-
term neuropsychological outcome following ECPR with formal
developmental testing are lacking (19).
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Change in Techniques, Devices, and
Medical Management During ECMO
Cardio-circulatory or respiratory failure, or a combination of
both, is a dynamic process. Traditionally, venovenous (VV-
ECMO) was provided for respiratory support and venoarterial
(VA-ECMO) for circulatory support. For neonates, VA-ECMO
was the preferred mode. Currently more hybrid forms of
ECMO are used. To provide sufficient regional and systemic
perfusion, cannulation for ECMO should be patient-tailored
(20).
While a CNS injury rate as high as 20% has been reported
in association with arterial cannulation, this rate is lower
in association with VV-ECMO (21). A recent survey of
the American Pediatric Surgical Association reported carotid
artery repair after decannulation in 6.6% of all patients and
in 10.7% of over 5 year old (22). The long-term effects
of carotid cannulation and subsequent repair still remain
unclear.
In adults, the stroke rate following arterial cannulation varied
with the cannulation site: 5.9–22.7% for femoral, 6.2–10.6% for
subclavian, 25% for carotid and 21.3% for aortic cannulation. In
a single center study in 36 children with a body weight of at least
15 kg, the prevalence of neurologic injury was 25% following neck
cannulation and 12% following femoral cannulation (23).
Traditional semi-occlusive roller pump ECMO systems with
silicone membrane oxygenators have almost universally been
replaced by centrifugal pumps and polymethylpentene diffusion
membrane oxygenators. These newer systems are much easier
to prime and require smaller priming volumes. Hemolysis has
been reported as a complication of the use of centrifugal pumps
in children (24). In other studies, however, pump type was not
associated with bleeding, thrombosis, hemolysis, or mortality
(25–27). The use of polymethylpentene oxygenators with less
thrombogenic properties was associated with a trend toward a
lower ICU mortality in patients. The question is whether the
use of these next generation ECMO systems will result in better
long-term outcome in children.
ECMO anticoagulation practices vary widely and have
changed over the years. Although the ELSO has issued a guideline
on the use of anticoagulation during ECMO (28), bleeding and
clotting are still a major issue. The level of anticoagulation has
to be judicially adjusted taking into account all complex factors
that may affect such as the the severity of illness, underlying
pathology and circuitry components. Bleeding occurred in
70% of a large cohort of pediatric ECMO patients, including
intracranial hemorrhage in 16% (27). Neither hemolysis nor
thrombotic events increased the risk of mortality (27).Thus,
adequate monitoring of the coagulation system remains crucial
and the level of anticoagulationmight impact long-term outcome
(29). Several high-volume ECMO centers from Canada, UK
and the Netherlands have recently initiated a consortium—
called the Phoenix consortium—to compare their standards of
care and to prepare RCTs to optimize (anti)coagulant therapy.
Although in a recent study in adult ECMO patients the benefit
of bivalirudin versus heparin could not be shown, future newer
types of anticoagulants may offer advantages (30).
THE PREVALENCE OF NEUROLOGICAL
MORBIDITIES AND THE ROLE OF
DIAGNOSTIC TOOLS
Children supported on ECMO are at risk of neurological
complications for a variety of reasons, ranging from poor
pre-ECMO clinical state, severe underlying diagnosis, ECMO
cannulation, systemic anticoagulation on ECMO, and other
on-ECMO and post-ECMO complications. They should be
carefully monitored, therefore, especially because they are
likely to be sedated. Detailed clinical examination should be
supplemented with cranial ultrasound scans (CUS), electro
encephalography (EEG), near infrared spectroscopy (NIRS),
transcranial Doppler, computer tomography (CT) brain and
serum bio-markers. None of these modalities is perfect on its
own, but in combination with good clinical examination and
close bedside review by the ECMO specialists, acute neurological
complications are likely to be identified and can be acted
upon. The most important neurological complications are CNS
hemorrhage and infarction, seizures, and, rarely, brain death
(31–34).
Hemorrhage and Infarction
Between 2013 and 2017, CNS hemorrhage occurred in 12%
of neonates undergoing respiratory ECMO, of whom 39%;
CNS infarction occurred in 4%. of whom 33% survived (1).
Corresponding figures for older children treated with ECMO
for respiratory failure were 7% CNS hemorrhages with a 23%
survival rate and 5% CNS infarctions with a 36% survival rate.
Seizures occurred in 8 and 4% of neonates and older children,
respectively, with survival rates of about 50 and 40% (1).
Cerebral lesions, including hemorrhage and ischemia, have
been reported in 10–52% of neonates (35–37).
Some papers specifically described posterior fossa lesions in
ECMO treated neonates (38, 39). It was speculated that ligation
of the right jugular vein and cannulation caused obstruction of
venous outflow and stasis, with the concomitant risk of rupture
of the periventricular medullary veins (40).
As it is unclear whether all patients in the ELSO registry
underwent neuro-imaging studies during and/or after ECMO, it
is well possible that CNS complications are underestimated. A
recent paper on serial CUS in 650 neonates treated with ECMO in
the period 1989-2010 reported brain abnormalities in 17.3% (41).
Primary hemorrhage was the most frequent abnormality (8.8%),
located intraventricular in half of the cases. Stroke was detected
in 5%, predominantly in the left hemisphere (70%). This was also
the dominant hemisphere for lobar hemorrhages (2.2%; 89% left)
(41). Seventy-five percent of the lesions were detected within the
first 72 h of the ECMO run (41). Interestingly, the incidences of
lesions had not changed over the years.
The ELSO recommends daily CUS in neonates after the start
of ECMO (1). CUS is easily applied at low costs and with
avoidance of radiation. Still, Biehl and coworkers suggested that
daily CUS are cost-effective only during the first 3 days of ECMO.
After 3 days, CUS is only indicated upon change in neurologic
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status or multi-organ failure, which events are both associated
with the occurrence of late hemorrhages (42).
Moreover, CUS might also be used for Doppler studies.
O’Brien and Hall demonstrated an increased risk for
hemorrhages in children aged 2 days-18 years, as blood
flow velocities measured in the middle cerebral artery were
higher (43). Zamora and coworkers found that variations
of more than 10% in the resistance index (i.e., peak systolic
velocity-end diastolic velocity)/peak systolic velocity) of the
anterior cerebral artery on any day of ECMO treatment were
related with cerebrovascular complications (44).
However, small ischemic and hemorrhagic lesions may be
difficult to recognize on CUS alone (35, 45, 46). Lesions that
determine later neurodevelopmental outcome might be more
microscopic and requiring specific imaging techniques. Pre-
discharge cerebral CT/MRI is advised to cover this (2).
Nowadays, MRI, for its high sensitivity and specificity to
detect stroke and white matter injuries, is considered the best
imaging technique to detect brain abnormalities related to
previous ECMO treatment (46, 47). It is contraindicated during
ECMO, however, and can only be performed after decannulation
and when the patient can be safely transported. Rollins and
coworkers showed that 50% of neonates with a normal CUS
had an abnormal MRI; non-hemorrhagic lesions were most often
missed by CUS (46). A CT scan is recommended on suspicion
of acute neurological cerebral complications. In the acute stage
of cerebral ischemia, 53% of the patients have normal CT scans
(48). Transport of the patient on ECMO for CT scanning can
be challenging. Moreover, the radiation exposure is another
disadvantage. Portable head CTs are available in some PICUs.
The effects on the brain of ligation of the right carotid
artery and jugular vein in VA-ECMO have been reason for
concern. Most studies did not find left-to-right hemisphere
differences for cerebral lesions (32–35, 45, 49). Still, Mendoza
and colleagues found that hemorrhages occurred more often in
the left hemisphere but ischemic lesions more often in the right
hemisphere (50). Hahn and colleagues found a predominance of
non-hemorrhagic lesions in the right hemisphere (51).
The effect of ECMO technique, VA versus VV, on the
incidence of cerebral lesions is still unknown. In a retrospective
study, the incidence of severe intracranial hemorrhage in VA-
ECMO treated newborns was higher than that in VV-ECMO
treated newborns (29 vs. 7%) (52).
Cerebral injury might originate from combinations of
pre-ECMO factors, patient-related factors, disease-related
factors and even factors related to ther ECMO treatment itself.
Possibly contributing factors are: acidosis, sepsis as primary
diagnosis, coagulopathy, heparinization, thrombocytopenia,
venous congestion due to jugular vein ligation, inflammatory
response on ECMO, and carotid artery ligation (53). Cerebral
autoregulation, which is the mechanism to maintain cerebral
blood flow over a wide range of cerebral perfusion pressures,
is disturbed in severely ill term infants and in newborn lambs
after hypoxia and/or ECMO treatment (54, 55). The cerebral
vasculature is therefore then highly vulnerable to blood pressure
changes, with risk of ischemic complications from hypoperfusion
and hemorrhagic lesions from hyperperfusion.
In a lamb model, cerebral blood flow was increased after
hypoxia and oxygen transport to the brain, although cerebral
oxygen metabolism was still maintained when the carotid
artery and jugular vein were ligated (56). With near infrared
spectrophotometry (NIRS) and Doppler ultrasound it could be
demonstrated that carotid artery ligation caused a temporary
decrease in cerebral oxygenation in both hemispheres (57, 58).
Initiation of ECMO led to a significant increase in cerebral blood
volume and cerebral blood flow velocity. All together these may
be risk factors for cerebral hemorrhages during ECMO treatment.
Furthermore, changes in ECMO flow during the ECMO run can
alter regional cerebral autoregulation, as was shown in a small
study using multichannel NIRS (12 channels) and wavelet cross
correlation of oxygenated hemoglobin with mean arterial blood
pressure (59).
Seizures
Seizures are related to a worse outcome but are usually only
registered during EEG (60). In particular in neonates and young
children, seizures can be subtle or subclinical and only detectable
by continuous EEG monitoring, which also gives information
about the background pattern, organization, and inter-ictal
burden (61–63). Changes in background pattern, in particular
in one hemisphere, can be a symptom of acute brain damage.
As a downside, prolonged EEG monitoring harms the patient’s
scalp, and many children develop edema during ECMO runs,
which can affect the EEG signal. This is why trained EEG staff
and neurologists should set up the montage and interpret the
EEG findings. Studies on continuous EEG monitoring in ECMO
patients have not been published.
Amplitude integrated EEG (aEEG), which compresses raw
EEG information from 1-2 channels, is commonly used as
an alternative for EEG–although it has a poor sensitivity in
seizure detection (25–84%) (64). Focal seizures and neonatal
seizures of very low frequency are likely be filtered out of
the aEEG trace (64). In a study in 26 neonates treated with
ECMO, subclinical seizures were detected in two cases; in seven
cases (38%) the aEEG findings were classified as moderately to
severely abnormal (65). In another aEEG study, in 20 ECMO-
treated neonates, severe abnormalities detected before and/or
during ECMO predicted death or moderate to severe intracranial
neuropathology, as confirmed by neuroimaging or autopsy (66).
Diagnostic Tools to Predict
Neurodevelopmental Outcome
Irrespective of the neuroimaging technique used, conflicting
results have been reported on the relation between imaging
abnormalities and long-term neurodevelopmental outcome.
Neonates with CUS abnormalities do not always develop
neurological disabilities (46, 67). The other way round, a normal
CUS does not guarantee normal neurodevelopment (35). The
correlation between early neurodevelopmental outcomes and CT
(37) or MRI (46) findings is poor. Still, neonates with increased
cerebrospinal fluid spaces seem to be at risk for impaired
neurodevelopmental outcome (68).
NIRS technology is a functional imaging technique that
employs low-energy optical radiation (mostly in 2–3 different
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wavelengths) to assess absorption changes in the underlying brain
tissue. These absorption changes reflect the changes in local
concentration of oxy- and deoxy-hemoglobin, which in turn are
related to and triggered by the alternation in neuronal activity.
In a recent case series in 34 neonates and infants younger than
3 months, continuous NIRS monitoring during ECMO revealed
reduced brain tissue oxygenation in non-survivors and patients
who had neurological injury on neuroimaging compared to
those with more favorable outcome. This observation suggests
a potential role for NIRS in prognostication-in spite of the fact
that the NIRS values can be influenced by several factors. The
threshold value for brain ischemia still needs to be established
(69).
LONG-TERM OUTCOMES
The long-term medical and developmental outcomes after
neonatal ECMO have recently been reviewed (70, 71). The
highlights from this review and recent literature are addressed
below. Note that such data are not available for ECMO for
respiratory failure in older children and for cardiovascular
disease requiring ECMO support (72, 73). The scarce data on
neurodevelopmental follow-up in older children will be discussed
below.
Medical Outcomes
Pulmonary Morbidity and Exercise Tolerance
Studies on long-term lung function after neonatal ECMO are
scarce. The findings can be summarized as follows. Mild airflow
obstruction with normal lung function and normal diffusion
capacity are mostly noted at follow up examinations (during
school age) (70). The underlying diagnosis—i.e., respiratory
distress syndrome or CDH—or the extent and duration of
barotrauma and oxygen therapy are considered as risk factors for
persisting respiratory morbidity (70, 74). Normal or decreased
exercise tolerance is seen at school age (70). There are no
comparable data on long-term pulmonary outcomes or exercise
tolerance in children who underwent ECMO treatment after the
neonatal period, due to many different underlying diagnoses and
institutional ECMO protocols.
Renal Function
Two-thirds of neonates receiving ECMO develop acute kidney
injury (AKI) (75). In a study in 3,865 critically ill children
aged 2 weeks to 18 years, those who needed ECMO treatment
were at risk for developing AKI (adjusted odds ratio 2.72) (76).
Long-term renal function testing after neonatal ECMO, both in
children with and without AKI at a mean age of eight years,
revealed at least one sign of chronic kidney disease in 54/169
(32%) of children (77).
Neurodevelopmental Outcomes
In the past 10 years, it has become more and more apparent
that growing up after treatment with neonatal ECMO might be
associated with long-term neurodevelopmental consequences.
Recent extensive neuropsychological assessment in school-age
children treated with neonatal ECMO has led to the delineation
of a specific neuropsychological profile in many of these patients.
FIGURE 1 | Common neurodevelopmental pathway following neonatal critical
illness. Survivors of neonatal critical illness share an increased risk of
hippocampal alterations due to vulnerability to common conditions associated
with neonatal critical illness, which leads to long-term memory deficits.
ECMO=extracorporeal membrane oxygenation. Reprinted from The Lancet
Child Adolesc Health Schiller et al. (83). Copyright 2018, with permission from
Elsevier.
Although IQ is generally within the average range throughout
development, specific sustained attention deficits and impaired
verbal and visuospatial memory, both immediate and delayed
recall, have been found at school-age (78–80). Similar outcomes
were described in 17-year-old neonatal ECMO survivors,
suggesting that these deficits persist into adolescence (81). These
findings suggest a “growing into deficit” phenomenon (82),
where subtle injuries in specific brain regions acquired in early
life become evident only later in life, at the time when those
brain regions are required for higher cognitive functioning (83)
(Figure 1).
The use of advanced neuroimaging techniques has shed
light on the underlying neurobiology of the long-term
neuropsychological deficits following neonatal ECMO.
Sophisticated neuroimaging methods to study the brain
revealed no differences in cortical thickness and global brain
volumes between neonatal ECMO survivors and healthy controls
at school-age (84). Nevertheless, the ECMO survivors had
significantly lower verbal memory than controls (85). It seems,
therefore, that the underlying brain injury in ECMO survivors
is more subtle and found in specific areas. In another study,
structural MRI in 12-year-old children who had experienced
neonatal hypoxia showed smaller hippocampal volume in the left
and right hemispheres, adjusted for total brain volume, compared
to healthy controls (86). These findings were replicated by our
group in school-age children treated with ECMO following
severe respiratory failure: their hippocampal volume specifically
associated with verbal memory was smaller than that in healthy
controls (87). Using diffusion tensor imaging (DTI), we further
showed that the global white matter microstructure in the former
patients was different from that in healthy controls, specifically
the white matter tracts of the cingulum and parahippocampal
part of the cingulum (87).
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The regions found to be affected following neonatal ECMO
in these studies are all part of the brain’s limbic system,
which rapidly develops from the third trimester of pregnancy
throughout the neonatal period (88, 89). As such, these areas
may be particularly vulnerable in critically ill newborns. In the
studies mentioned above, only limited cognitive assessment was
available. Therefore, the underlying neurobiological correlates
of the observed sustained attention and visuospatial memory
deficits, in addition to verbal memory deficits, following neonatal
ECMO remained unknown. In a different cohort of school-
age (8–12 years) survivors of neonatal ECMO following severe
respiratory failure and CDH, DTI, and structural MRI were
combined with elaborate neuropsychological assessment to assess
whether the previously shown brain alterations were associated
with the specific attention and memory deficits observed (80).
Again, we found that smaller hippocampal volume in ECMO
survivors was associated with worse verbal memory (80).
Furthermore, lower global fractional anisotropy (FA), which is
generally interpreted as reduced coherence of white matter fibers
(90), was associated with worse sustained attention (80). Higher
mean diffusivity, suggestive of decreased integrity in axonal
membranes, packing, or myelin (90), in the parahippocampal
part of the cingulum was associated with worse visuospatial
memory (80).
Taken together, these findings indicate that neonatal ECMO
is associated with specific neurobiological alterations in the
neuropsychological profile. As these children seem to “grow into
their deficits,” it is imperative that structured, problem-oriented
neuropsychological follow up throughout childhood and into
adolescence is indicated. This is underlined by the high number
of neonatal ECMO survivors who need extra help in school,
despite normal intellectual abilities (79).
Of eight available studies on long-term neurological outcome
in children who needed ECMO for cardiac failure, only four
actually performed age-appropriate neuropsychiatric tests (73).
The proportion of children available for follow-up ranged from
26-51% (73) and the cohorts overlap in two of these studies
(91, 92). In a Canadian study in four centers, 42 percent of the 98
children requiring VA-ECMO for cardiac disease were neonates
and all 44 survivors without chromosomal abnormality were
assessed at a mean age of 52 months. The mean IQ was 79.7, and
25% of children had an IQ below−2 SD (91). The same group
reported on neurodevelopmental outcomes in a subset of 17 five-
year-old ECPR survivors with cardiac disease who were assessed
at least 6 months after ECPR. This subset had a mean IQ of 76.5,
and 24% had an IQ below−2 SD (93). Wagner and coworkers
evaluated 14 children who underwent ECMO (10 for cardiac
disease and 4 for respiratory failure) after the first month of life
at a mean age of 7.2 years. The total study cohort consisted of
22 participants (8 neonatal ECMO cases) born between 1991 and
2004 (94). The mean IQ of these 22 children was 74.7. In 2003,
Hamrick and coworkers reported neurodevelopmental outcome
at a median age of 55 months in 14 cardiac ECMO survivors. The
median age at initiation of ECMO treatment was 27 days, which
implies that only half of this cohort underwent ECMO beyond
the neonatal period. Evaluation revealed normal cognition in
50% and normal neuromotor outcome in 72% (95).
CURRENT STATUS OF FOLLOW-UP
PROGRAMS
The current recommendations for long-term follow-up
published by ELSO have been established in 1994 and were
reviewed in 1997 (96). Based on the knowledge available at that
time, ELSO recommended to discontinue follow up after the age
of 5 years and perform one assessment after 6 months in those
who needed ECMO support during childhood.
Only very few ECMO centers in the world provide
comprehensive multi-disciplinary follow up right from the
time of discharge from hospital to adolescence. The 10 years’
experience of a single center follow-up program in the UK for
children supported for respiratory ECMO has recently been
published (97). Follow-up was offered to all 194 survivors at the
age of 1 year. Neurodevelopmental problems were identified in
30% of 98 participants, but alarmingly, 66 of 96 non-participants
(34% of all ECMO survivors) were completely lost to follow-up
and did not seem to attend local health care services (97). Most
data on long-term outcomes after neonatal ECMO have become
available from a nationwide longitudinal follow-up program
in the Netherlands, which is offered as standard of care to
all neonates and children discharged after ECMO treatment
(98). Seventy-nine percent attended the follow-up program at
8 years (99) and 63% underwent medical and developmental
evaluation including neuropsychological assessment at 17–18
years (81).
Standardized Clinical Assessment and
Management Pathway; The UK Experience
In 2010, Rathod et al. proposed a novel methodology to
aid the rationalization of clinical management and permit
evolution of care pathways (100). This methodology is founded
on the understanding that most clinical decisions are not
necessarily evidence-based, and that there must be provision
for flexibility in relation to changing practice. As part of
the quality improvement project, an attempt was made to
establish a collaborative Standardized Clinical Assessment
and Management Pathway (SCAMP) for neurodevelopmental
outcome between ECMO centers in the UK. In accordance
with the difference steps in SCAMP, published literature,
international recommendations and local guidelines were
reviewed. Expertise from the fields of neurology, neuroradiology
and neuropsychology was sought and a consensus was evolved
through a series of local and national specialist group meetings.
The aim of this initiative was to identify surveillance, screening
and early interventions to improve the level of functional
neurodevelopment, quality of life and family satisfaction in
children post mechanical support. A framework for cyclical
analysis was defined, allowing variability in outcomes to
emerge alongside refinements in care and resource utilization.
Although SCAMPs can potentially reduce resource utilization
and costs, as recently evidenced for treatment with arterial switch
operations (101), available resources are currently insufficient
to guarantee neurodevelopmental assessments in the long
run.
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FIGURE 2 | Schematic representation of a standardized multidisciplinary
approach to optimize care. RCT = randomized controlled trial. Reprinted from
Sem Pediatr Surg, Vol 26, IJsselstijn H et al., Assessment and significance of
long-term outcomes in pediatric surgery, Pages 281–285, Copyright 2017,
with permission from Elsevier.
The Importance of Age-Appropriate
Follow-Up Programs
For clinicians it is important to know about long-term
morbidities as more children with severe comorbidities will
survive. They may, therefore, be confronted with problems
never encountered in the past. Moreover, as functional outcomes
may be related to treatment, evaluation of long-term effects of
treatment interventions or after implementation of standardized
postnatal treatment protocols is important.
From the patients’ perspective, knowledge on long-term
morbidities will help to recognize problems at an early stage so
that timely intervention can be offered. For instance, a patient
should be referred to a pediatric physical therapist if gross motor
function problems that have implications for everyday activities
persist. Explaining expected long-term outcomes to the child, its
parents and other caregivers will have a stimulating effect on
care domains such as self-management, family empowerment,
and education (102). Awaiting further research, we hypothesize
that long-term follow-up programs are cost-effective as family
empowerment is expected to improve outcome and education
of other caregivers may result in targeted evaluation without
redundant tests. Moreover, outcome research data can form
a basis for randomized clinical trials that lead to improved
care (Figure 2). Such a randomized controlled trial, on the
effectiveness of a working-memory training on improving long-
term neuropsychological outcome following neonatal ECMO
and/or CDH, showed sustained improvements in visuospatial




Recommendations for long-term follow up depend on the
presence of neurological comorbidity, the nature and extent of
the underlying disease, and the indication for ECMO. In any
case it should preferably be offered as standard of care, and
in a structured and standardized way. This permits to evaluate
outcome data and effects of interventions. Such a program would
preferably be offered within the ECMO center, but could also
be provided by community pediatricians and other health care
providers near home. As neurodevelopment is usually normal
within the first years of life, health care providers and parents
may be inclined to disregard the necessity of regular follow-
up visits. Based on current knowledge on long-term outcomes
and the phenomenon that survivors of ECMO may “grow
into their deficits,” health care providers working in ECMO
centers should inform parents about potential sequelae and urge
them to seek advice in case of unexplained growth failure,
reduced exercise tolerance or neurodevelopmental problems
such as clumsiness, failure of academic performance, behavioral
problems or impaired attention, concentration, or memory.
We propose the following flowchart for follow-up as standard
of care (Figure 3).
Children with neurological comorbidity should be referred
to a neurologist and/or a rehabilitation center. Also in case
of suspected neurological comorbidity that is not evident
at discharge, referral to a pediatric neurologist and/or a
developmental pediatrician is recommended. Moreover, if
children suffer from underlying disease (e.g. cardiovascular
disease or lung function impairment) additional disease-specific
follow-up should be arranged.
The majority of children (i.e., up to 85–90%) may be
discharged from the ICU without neurological comorbidity.
Children without neurological comorbidity at discharge
should be referred for disease-specific follow-up if applicable.
Both for children with or without underlying disease (e.g.,
respiratory neonatal ECMO for MAS), a long-term follow-up
program with regular assessments covering various medical and
neurodevelopmental domains is recommended (Table 1).
From the current literature it is unknown whether children
who need ECMO at older age have similar long-term problems
as neonatal ECMO survivors. As somatic problems may occur
at any age and brain development including myelinization
continues up till adolescence, it can be assumed that also pediatric
ECMO survivors benefit from long-term follow-up and timely
interventions.
RISK STRATIFICATION
Interestingly, the neurodevelopmental outcomes in patients
treated with neonatal ECMO following severe respiratory
failure resemble those of patients treated with conventional
management (86), and do not differ between children with
congenital diaphragmatic hernia treated with and without
ECMO (78, 80, 104). These findings suggest that, rather than
treatment or underlying disease, similar factors associated with
critical illness may be involved in the long-term sequelae
(83). Risk stratification should therefore not only focus on the
ECMO treatment and post-discharge assessments but also take
into account the underlying pathology, disease severity and
treatment-related morbidities such as infections and coagulation
problems. The latter morbidities are considered as iatrogenic
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FIGURE 3 | Flowchart for long-term follow-up of ECMO survivors. +: indicates condition present; – indicates condition absent, (a) e.g., cardiovascular disease,
pulmonary disease, genetic syndrome, psychiatric disease (including delirium, post-traumatic stress disorder or anxiety disorder following critical illness) (b) see
Table 1 for domains that should be covered in follow-up of ECMO survivors without (serious) neurologic comorbidity.
risk factors that sometimes significantly affect overall outcome.
Different options that may be helpful to risk stratification are
discussed below.
Registries
In pediatric critical care medicine, many registries collect data
of variable levels of clinical detail–ranging from vital signs
and laboratory results (high clinical detail) to demographic
and administrative data (low clinical detail) (105). To date,
several large, multi-center prospective registry datasets provide
important clinical information about a population that is
heterogeneous with respect to age and comorbidities at PICU
admission (106). Apart from these registries and disease-specific
registries, therapy-specific registries are available, such as the
ELSO Registry (105). The ELSO registry was set up to provide
member institutions with data to benchmark their results against
that of other institutions, to improve quality of care to patients,
and to achieve cost-effectiveness. Registered data include sex,
ethnicity, nature and severity of illness, technical details
of extracorporeal support used, complications and outcome1
Combining data from the large pediatric critical care datasets,
the disease-specific registries, the ELSO Registry and long-
term outcome data would be very helpful to determine which
children are at risk for long-term morbidities and personalized
care pathways can be offered at PICU discharge. However, we
have to realize that registries are generally based on voluntary
data provision without standardized quality control, which may
influence the results.




Children at risk of neuropsychological impairments and
academic problems following neonatal ECMO should be
identified as early as possible and supported. Neuropsychological
assessment is needed to identify children at risk of school
problems. Since higher-order cognitive functions, such as
memory, are still developing throughout early childhood, results
of such assessments cannot be interpreted reliably until school
age (107). In practice, children who already experience problems
are offered neuropsychological assessment, which thus is a
diagnostic tool rather than a prediction tool. It would be valuable
to find predictors for later school problems that can be assessed
as early as in infancy.
Promising in this respect is MRI scanning, which is non-
invasive and can be reliably performed in infants without
sedation (108, 109). Hippocampal volume alterations detected
in infancy with MRI could potentially serve to predict memory
deficits later in childhood. For instance, hippocampal volumes
in preterm infants measured at term-equivalent age were
found to correlate with memory outcomes both at 2 years
and seven years of age (108, 109). Future studies aimed at
finding normative infant hippocampal volumes are a first
step toward early risk stratification using MRI in critically ill
infants. Furthermore, as the hippocampus is rapidly growing
during the first two years of life (110), longitudinal studies
will determine the optimum timing to assess hippocampal
morphology. Longitudinal studies can provide more insight
in the association between neurodevelopmental outcome
and clinical characteristics, and contribute to early risk
stratification. As a complex interplay among different factors
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TABLE 1 | Proposal for and relevance of long-term follow-up after (neonatal) ECMO.





Neurologic assessment including imaging
Mental development
Motor development





























Hypertension, urinary protein-to-creatinine ratio
Spirometry








Evaluate reversibility of airflow obstruction
Referral physical therapist
Sports participation and/or exercise training
Referral to early school support
Referral to cognitive rehabilitation
Referral to support/guidance
ADOLESCENCE






Hypertension, urinary protein-to-creatinine ratio









Referral physical therapist/sports participation
Sports participation/exercise training
Referral to school support
Career support/choice of profession
Referral to cognitive rehabilitation
Referral to support/guidance
ECMO, extracorporeal membrane oxygenation; CKD, chronic kidney disease; CDH, congenital diaphragmatic hernia.
associated with the underlying disease, pharmacological and
non-pharmacological treatment and “iatrogenesis” is likely to
determine a child’s neurodevelopmental outcome (83), detailed




Since the introduction of extracorporeal life support several
decades ago (111), the population, devices and techniques
have changed and more children survive. Interest has therefore
shifted from reduction of mortality toward prevention of
morbidity. Nowadays, more and more clinicians become aware
that multidisciplinary long-term follow up should be offered to
ECMO survivors.
To optimize care as suggested in Figure 2, several issues
need to be resolved on the way to uniform data collection
in a multicenter international registry of long-term outcome
data. First, treatment protocols, including recommendations
for neuromonitoring in the ICU, need further standardization.
Although registered long-term outcome data may be useful
to compare different treatment strategies, a minimum set of
uniform treatment criteria, baseline data, and a substantial
number of participating centers are required for the detection of
statistically significant differences. Second, one uniform follow-
up program should be applied. Frequent revision of the follow-
up guidelines—accounting for new treatment modalities—is
an important first step. Moreover, assessment instruments
and outcome scores need to be standardized and validated
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and population-specific standard deviation scores should be
obtained. Third, health care policy makers need to realize that
sufficient resources must be ensured, not only to make long-
term follow-up possible, but also to set up registries meeting
the institutional criteria of data management for all participants
and to maintain registries both at a local and a central level.
Organizations such as ELSO and international societies of
pediatric and neonatal intensive care should have an important
role in facilitating multicenter collaboration and to support
initiatives to obtain sufficient funding.
AUTHOR CONTRIBUTIONS
HI, MH, RS, RH, AH, and AvH: drafted the manuscript. All
authors contributed to critical revision of the manuscript and
approved the final version before submission.
REFERENCES
1. Extracorporeal Life Support Organization. ECLS Registry Report
International Summary January, 2018. Ann Arbor, MI (2018).
2. Gray BW, Rintoul NE. ELSO Guidelines for Cardiopulmonary Extracorporeal
Life Support. Extracorporeal Life Support Organization (2017). Available
from: https://www.elso.org/resources/guidelines.aspx
3. MacLaren G, Conrad S, Peek G. Indications for Pediatric Respiratory
Extracorporeal Life Support. Ann Arbor, MI: ELSO. (2015)
4. Brogan TV, Zabrocki L, Thiagarajan RR, Rycus PT, Bratton SL.
Prolonged extracorporeal membrane oxygenation for children
with respiratory failure. Pediatr Crit Care Med. (2012) 13:e249–54.
doi: 10.1097/PCC.0b013e31824176f4
5. Bennett CC, Johnson A, Field DJ, Elbourne D, Group UKCET. UK
collaborative randomised trial of neonatal extracorporeal membrane
oxygenation: follow-up to age 4 years. Lancet (2001) 357:1094–6.
doi: 10.1016/S0140-6736(00)04310-5
6. Peek GJ, Mugford M, Tiruvoipati R, Wilson A, Allen E, Thalanany
MM, et al. Efficacy and economic assessment of conventional
ventilatory support versus extracorporeal membrane oxygenation for
severe adult respiratory failure (CESAR): a multicentre randomised
controlled trial. Lancet (2009) 374:1351–63. doi: 10.1016/S0140-6736(09)
61069-2
7. Barbaro RP, Xu Y, Borasino S, Truemper EJ, Watson RS, Thiagarajan
RR, et al. Does extracorporeal membrane oxygenation improve survival in
pediatric acute respiratory failure? Am J Respir Crit Care Med. (2018)
197:1177–86. doi: 10.1164/rccm.201709-1893OC
8. Carpenter TC, Kinsella JP. Waiting for godot: clinical trials of ECMO for
pediatric respiratory failure. Am J Respir Crit Care Med. (2018) 197:1103–4.
doi: 10.1164/rccm.201802-0268ED
9. Cashen K, Reeder R, Dalton HJ, Berg RA, Shanley TP, Newth CJL, et al.
Functional status of neonatal and pediatric patients after extracorporeal
membrane oxygenation. Pediatr Crit Care Med. (2017) 18:561–70.
doi: 10.1097/PCC.0000000000001155
10. Prodhan P, Stroud M, El-Hassan N, Peeples S, Rycus P, Brogan
TV, et al. Prolonged extracorporeal membrane oxygenator support
among neonates with acute respiratory failure: a review of the
Extracorporeal Life Support Organization registry. ASAIO J. (2014)
60:63–9. doi: 10.1097/MAT.0000000000000006
11. Vivian-Taylor J, Sheng J, Hadfield RM, Morris JM, Bowen JR,
Roberts CL. Trends in obstetric practices and meconium aspiration
syndrome: a population-based study. BJOG (2011) 118:1601–7.
doi: 10.1111/j.1471-0528.2011.03093.x
12. Paden ML, Rycus PT, Thiagarajan RR, Registry E. Update and outcomes
in extracorporeal life support. Semin Perinatol. (2014) 38:65–70.
doi: 10.1053/j.semperi.2013.11.002
13. de Caen AR, Berg MD, Chameides L, Gooden CK, Hickey RW, Scott
HF, et al. Part 12: pediatric advanced life support: 2015 American
Heart association guidelines update for cardiopulmonary resuscitation and
emergency cardiovascular care. Circulation (2015) 132(18 Suppl. 2):S526–42.
doi: 10.1161/CIR.0000000000000266
14. Thiagarajan RR, Laussen PC, Rycus PT, Bartlett RH, Bratton SL.
Extracorporeal membrane oxygenation to aid cardiopulmonary
resuscitation in infants and children. Circulation (2007) 116:1693–700.
doi: 10.1161/CIRCULATIONAHA.106.680678
15. Chen YS, Lin JW, Yu HY, Ko WJ, Jerng JS, Chang WT, et al.
Cardiopulmonary resuscitation with assisted extracorporeal life-support
versus conventional cardiopulmonary resuscitation in adults with in-
hospital cardiac arrest: an observational study and propensity analysis.
Lancet (2008) 372:554–61. doi: 10.1016/S0140-6736(08)60958-7
16. Dennis M, McCanny P, D’Souza M, Forrest P, Burns B, Lowe DA,
et al. Extracorporeal cardiopulmonary resuscitation for refractory
cardiac arrest: a multicentre experience. Int J Cardiol. (2017) 231:131–6.
doi: 10.1016/j.ijcard.2016.12.003
17. Cesana F, Avalli L, Garatti L, Coppo A, Righetti S, Calchera I, et al.
Effects of extracorporeal cardiopulmonary resuscitation on neurological and
cardiac outcome after ischaemic refractory cardiac arrest. Eur Heart J Acute
Cardiovasc Care (2017). doi: 10.1177/2048872617737041. [Epub ahead of
print].
18. Turek JW, Andersen ND, Lawson DS, Bonadonna D, Turley RS, Peters
MA, et al. Outcomes before and after implementation of a pediatric rapid-
response extracorporeal membrane oxygenation program. Ann Thorac Surg.
(2013) 95:2140–6; discussion 6-7. doi: 10.1016/j.athoracsur.2013.01.050
19. Joffe AR, Lequier L, Robertson CM. Pediatric outcomes after extracorporeal
membrane oxygenation for cardiac disease and for cardiac arrest: a review.
ASAIO J. (2012) 58:297–310. doi: 10.1097/MAT.0b013e31825a21ff
20. Sorokin V, MacLaren G, Vidanapathirana PC, Delnoij T, Lorusso R.
Choosing the appropriate configuration and cannulation strategies for
extracorporeal membrane oxygenation: the potential dynamic process of
organ support and importance of hybrid modes. Eur J Heart Fail. (2017)
19(Suppl. 2):75–83. doi: 10.1002/ejhf.849
21. Rollins MD, Hubbard A, Zabrocki L, Barnhart DC, Bratton SL.
Extracorporeal membrane oxygenation cannulation trends for pediatric
respiratory failure and central nervous system injury. J Pediatr Surg. (2012)
47:68–75. doi: 10.1016/j.jpedsurg.2011.10.017
22. Garcia AV, Jeyaraju M, Ladd MR, Jelin EB, Bembea MM, Alaish
S, et al. Survey of the american pediatric surgical association on
cannulation practices in pediatric ECMO. J Pediatr Surg. (2017).
doi: 10.1016/j.jpedsurg.2017.11.046. [Epub ahead of print].
23. Kurkluoglu M, Hynes CF, Alfares FA, El-Sayed Ahmed MM, Peer SM,
Zurakowski D, et al. Choice of peripheral venoarterial extra-corporeal
membrane oxygenation cannulation site in patients above 15 kilograms. J
Card Surg. (2015) 30:461–5. doi: 10.1111/jocs.12538
24. Lou S, MacLaren G, Best D, Delzoppo C, Butt W. Hemolysis in pediatric
patients receiving centrifugal-pump extracorporeal membrane oxygenation:
prevalence, risk factors, and outcomes. Crit Care Med. (2014) 42:1213–20.
doi: 10.1097/CCM.0000000000000128
25. O’Brien C, Monteagudo J, Schad C, Cheung E, Middlesworth W.
Centrifugal pumps and hemolysis in pediatric extracorporeal membrane
oxygenation (ECMO) patients: an analysis of Extracorporeal Life Support
Organization (ELSO) registry data. J Pediatr Surg. (2017) 52:975–8.
doi: 10.1016/j.jpedsurg.2017.03.022
26. Barrett CS, Jaggers JJ, Cook EF, Graham DA, Yarlagadda VV, Teele SA,
et al. Pediatric ECMO outcomes: comparison of centrifugal versus roller
blood pumps using propensity score matching. ASAIO J. (2013) 59:145–51.
doi: 10.1097/MAT.0b013e31828387cd
27. Dalton HJ, Reeder R, Garcia-Filion P, Holubkov R, Berg RA, Zuppa A, et al.
Factors associated with bleeding and thrombosis in children receiving
extracorporeal membrane oxygenation. Am J Respir Crit Care Med. (2017)
196:762–71. doi: 10.1164/rccm.201609-1945OC
Frontiers in Pediatrics | www.frontiersin.org 10 June 2018 | Volume 6 | Article 177
IJsselstijn et al. Long-Term Follow-Up After ECMO
28. ELSO. ELSO Anticoagulation Guideline. Ann Arbor, MI: ELSO (2014).
29. Anton-Martin P, Journeycake J, Modem V, Golla S, Raman L, Tweed J, et al.
Coagulation profile is not a predictor of acute cerebrovascular events in
pediatric extracorporeal membrane oxygenation patients. ASAIO J. (2017)
63:793–801. doi: 10.1097/MAT.0000000000000571
30. Berei TJ, Lillyblad MP, Wilson KJ, Garberich RF, Hryniewicz KM.
Evaluation of systemic heparin versus bivalirudin in adult patients:
supported by extracorporeal membrane oxygenation. ASAIO J. (2017).
doi: 10.1097/MAT.0000000000000691. [Epub ahead of print].
31. Bulas DI, Glass P, O’Donnell RM, Taylor GA, Short BL, Vezina GL. Neonates
treated with ECMO: predictive value of early CT and US neuroimaging
findings on short-term neurodevelopmental outcome. Radiology (1995)
195:407–12. doi: 10.1148/radiology.195.2.7536947
32. Bulas DI, Taylor GA, O’Donnell RM, Short BL, Fitz CR, Vezina G.
Intracranial abnormalities in infants treated with extracorporeal membrane
oxygenation: update on sonographic and CT findings. AJNR Am J
Neuroradiol. (1996) 17:287–94.
33. Glass P, Miller M, Short B. Morbidity for survivors of extracorporeal
membrane oxygenation: neurodevelopmental outcome at 1 year of age.
Pediatrics (1989) 83:72–8.
34. Taylor GA, Short BL, Fitz CR. Imaging of cerebrovascular injury in
infants treated with extracorporeal membrane oxygenation. J Pediatr. (1989)
114(4 Pt 1):635–9. doi: 10.1016/S0022-3476(89)80711-5
35. Lazar EL, Abramson SJ, Weinstein S, Stolar CJ. Neuroimaging of brain
injury in neonates treated with extracorporeal membrane oxygenation:
lessons learned from serial examinations. J Pediatr Surg. (1994) 29:186–90;
discussion 90-1. doi: 10.1016/0022-3468(94)90315-8
36. Graziani LJ, Gringlas M, Baumgart S. Cerebrovascular complications and
neurodevelopmental sequelae of neonatal ECMO. Clin Perinatol. (1997)
24:655–75. doi: 10.1016/S0095-5108(18)30163-5
37. Bulas D, Glass P. Neonatal ECMO: neuroimaging and
neurodevelopmental outcome. Semin Perinatol. (2005) 29:58–65.
doi: 10.1053/j.semperi.2005.02.009
38. Bulas DI, Taylor GA, Fitz CR, Revenis ME, Glass P, Ingram JD. Posterior
fossa intracranial hemorrhage in infants treated with extracorporeal
membrane oxygenation: sonographic findings. Am J Roentgenol. (1991)
156:571–5. doi: 10.2214/ajr.156.3.1899761
39. Wiznitzer M, Masaryk TJ, Lewin J, Walsh M, Stork EK. Parenchymal and
vascular magnetic resonance imaging of the brain after extracorporeal
membrane oxygenation. Am J Dis Child. (1990) 144:1323–6.
doi: 10.1001/archpedi.1990.02150360047018
40. Taylor GA, Walker LK. Intracranial venous system in newborns treated
with extracorporeal membrane oxygenation: doppler US evaluation
after ligation of the right jugular vein. Radiology (1992) 183:453–6.
doi: 10.1148/radiology.183.2.1561349
41. Raets MM, Dudink J, Ijsselstijn H, van Heijst AF, Lequin MH,
Houmes RJ, et al. Brain injury associated with neonatal extracorporeal
membrane oxygenation in the Netherlands: a nationwide evaluation
spanning two decades. Pediatr Crit Care Med. (2013) 14:884–92.
doi: 10.1097/PCC.0b013e3182a555ac
42. Biehl DA, Stewart DL, Forti NH, Cook LN. Timing of intracranial
hemorrhage during extracorporeal life support. ASAIO J. (1996) 42:938–41.
doi: 10.1097/00002480-199642060-00003
43. O’Brien NF, Hall MW. Extracorporeal membrane oxygenation and cerebral
blood flow velocity in children. Pediatr Crit Care Med. (2013) 14:e126–34.
doi: 10.1097/PCC.0b013e3182712d62
44. Zamora CA, Oshmyansky A, Bembea M, Berkowitz I, Alqahtani E, Liu S,
et al. Resistive index variability in anterior cerebral artery measurements
during daily transcranial duplex sonography: a predictor of cerebrovascular
complications in infants undergoing extracorporeal membrane oxygenation?
J Ultrasound Med. (2016) 35:2459–65. doi: 10.7863/ultra.15.09046
45. BabcockDS, Han BK,Weiss RG, Ryckman FC. Brain abnormalities in infants
on extracorporeal membrane oxygenation: sonographic and CT findings.
Am J Roentgenol. (1989) 153:571–6. doi: 10.2214/ajr.153.3.571
46. Rollins MD, Yoder BA, Moore KR, Barnhart DC, Jones C, Null DM, et al.
Utility of neuroradiographic imaging in predicting outcomes after neonatal
extracorporeal membrane oxygenation. J Pediatr Surg. (2012) 47:76–80.
doi: 10.1016/j.jpedsurg.2011.10.016
47. Wien MA, Whitehead MT, Bulas D, Ridore M, Melbourne L, Oldenburg
G, et al. Patterns of Brain Injury in Newborns Treated with Extracorporeal
Membrane Oxygenation. AJNR Am J Neuroradiol. (2017) 38:820–6.
doi: 10.3174/ajnr.A5092
48. Rafay MF, Pontigon AM, Chiang J, Adams M, Jarvis DA, Silver F, et al.
Delay to diagnosis in acute pediatric arterial ischemic stroke. Stroke (2009)
40:58–64. doi: 10.1161/STROKEAHA.108.519066
49. Campbell LR, Bunyapen C, Holmes GL, Howell CG, Jr., Kanto WP, Jr. Right
common carotid artery ligation in extracorporeal membrane oxygenation. J
Pediatr. (1988) 113(1 Pt 1):110–3. doi: 10.1016/S0022-3476(88)80543-2
50. Mendoza JC, Shearer LL, Cook LN. Lateralization of brain lesions following
extracorporeal membrane oxygenation. Pediatrics (1991) 88:1004–9.
51. Hahn JS, Vaucher Y, Bejar R, Coen RW. Electroencephalographic and
neuroimaging findings in neonates undergoing extracorporeal membrane
oxygenation. Neuropediatrics. (1993) 24:19–24. doi: 10.1055/s-2008-10
71507
52. Varnholt V, Lasch P, Sartoris J, Koelfen W, Kachel W, Lorenz C, et
al. Prognosis and outcome of neonates treated either with veno-arterial
(VA) or veno-venous (VV) ECMO. Int J Artif Organs. (1995) 18:569–73.
doi: 10.1177/039139889501801004
53. Short BL. The effect of extracorporeal life support on the
brain: a focus on ECMO. Semin Perinatol. (2005) 29:45–50.
doi: 10.1053/j.semperi.2005.02.007
54. Short BL, Walker LK, Traystman RJ. Impaired cerebral autoregulation in the
newborn lamb during recovery from severe, prolonged hypoxia, combined
with carotid artery and jugular vein ligation. Crit Care Med. (1994) 22:1262–
8. doi: 10.1097/00003246-199408000-00010
55. Boylan GB, Young K, Panerai RB, Rennie JM, Evans DH. Dynamic
cerebral autoregulation in sick newborn infants. Pediatr Res. (2000) 48:12–7.
doi: 10.1203/00006450-200007000-00005
56. Short BL, Bender K, Walker LK, Traystman RJ. The cerebrovascular
response to prolonged hypoxia with carotid artery and jugular vein
ligation in the newborn lamb. J Pediatr Surg. (1994) 29:887–91.
doi: 10.1016/0022-3468(94)90009-4
57. Van Heijst A, Liem D, Hopman J, Van Der Staak F, Sengers R. Oxygenation
and hemodynamics in left and right cerebral hemispheres during induction
of veno-arterial extracorporeal membrane oxygenation. J Pediatr. (2004)
144:223–8. doi: 10.1016/j.jpeds.2003.11.006
58. Liem KD, Hopman JC, Oeseburg B, de Haan AF, Festen C, Kollee
LA. Cerebral oxygenation and hemodynamics during induction of
extracorporeal membrane oxygenation as investigated by near infrared
spectrophotometry. Pediatrics (1995) 95:555–61.
59. Papademetriou MD, Tachtsidis I, Elliot MJ, Hoskote A, Elwell
CE. Multichannel near infrared spectroscopy indicates regional
variations in cerebral autoregulation in infants supported on
extracorporeal membrane oxygenation. J Biomed Opt. (2012) 17:067008.
doi: 10.1117/1.JBO.17.6.067008
60. Lin JJ, Banwell BL, Berg RA, Dlugos DJ, Ichord RN, Kilbaugh TJ,
et al. Electrographic seizures in children and neonates undergoing
extracorporeal membrane oxygenation. Pediatr Crit Care Med. (2017)
18:249–57. doi: 10.1097/PCC.0000000000001067
61. Murray DM, Boylan GB, Ali I, Ryan CA, Murphy BP, Connolly S. Defining
the gap between electrographic seizure burden, clinical expression and staff
recognition of neonatal seizures. Arch Dis Child Fetal Neonatal Ed. (2008)
93:F187–91. doi: 10.1136/adc.2005.086314
62. Scher MS, Aso K, Beggarly ME, Hamid MY, Steppe DA, Painter MJ.
Electrographic seizures in preterm and full-term neonates: clinical correlates,
associated brain lesions, and risk for neurologic sequelae. Pediatrics (1993)
91:128–34.
63. Piantino JA, Wainwright MS, Grimason M, Smith CM, Hussain E, Byron
D, et al. Nonconvulsive seizures are common in children treated with
extracorporeal cardiac life support. Pediatr Crit Care Med. (2013) 14:601–9.
doi: 10.1097/PCC.0b013e318291755a
64. Glass HC, Wusthoff CJ, Shellhaas RA. Amplitude-integrated electro-
encephalography: the child neurologist’s perspective. J Child Neurol. (2013)
28:1342–50. doi: 10.1177/0883073813488663
65. Horan M, Azzopardi D, Edwards AD, Firmin RK, Field D. Lack of influence
of mild hypothermia on amplitude integrated-electroencephalography in
Frontiers in Pediatrics | www.frontiersin.org 11 June 2018 | Volume 6 | Article 177
IJsselstijn et al. Long-Term Follow-Up After ECMO
neonates receiving extracorporeal membrane oxygenation. Early Hum Dev.
(2007) 83:69–75. doi: 10.1016/j.earlhumdev.2006.05.004
66. Pappas A, Shankaran S, Stockmann PT, Bara R. Changes in amplitude-
integrated electroencephalography in neonates treated with extracorporeal
membrane oxygenation: a pilot study. J Pediatr. (2006) 148:125–7.
doi: 10.1016/j.jpeds.2005.07.044
67. Glass P, Bulas DI, Wagner AE, Rajasingham SR, Civitello LA, Papero PH,
et al. Severity of brain injury following neonatal extracorporeal membrane
oxygenation and outcome at age 5 years. Dev Med Child Neurol. (1997)
39:441–8. doi: 10.1111/j.1469-8749.1997.tb07463.x
68. Lago P, Rebsamen S, Clancy RR, Pinto-Martin J, Kessler A,
Zimmerman R, et al. MRI, MRA, and neurodevelopmental outcome
following neonatal ECMO. Pediatr Neurol. (1995) 12:294–304.
doi: 10.1016/0887-8994(95)00047-J
69. Clair MP, Rambaud J, Flahault A, Guedj R, Guilbert J, Guellec I, et
al. Prognostic value of cerebral tissue oxygen saturation during neonatal
extracorporeal membrane oxygenation. PLoS ONE (2017) 12:e0172991.
doi: 10.1371/journal.pone.0172991
70. Ijsselstijn H, Van Heijst AFJ. Long-term outcome of children treated
with neonatal extracorporeal membrane oxygenation: increasing
problems with increasing age. Semin Perinatol. (2014) 38:114–21.
doi: 10.1053/j.semperi.2013.11.009
71. Ijsselstijn H, Madderom MJ, Hoskote A. Outcomes, complications, and
followup of neonates with respiratory failure. In: Brogan TV, Lequier L,
Lorusso R, MacLaren G, Peek G, editors. Extracorporeal Life Support: The
ELSO Red Book. 5th Edn. Ann Arbor, MI: ELSO (2017). pp. 217–30.
72. Prodhan P. Outcomes, Complications, and Followup of Children with
Respiratory Failure. In: Brogan TV, Lequier L, Lorusso R, MacLaren G, Peek
G, editors. Extracorporeal Life Support: The ELSO Red Book. 5th Edn: ELSO
(2017). p. 297-305.
73. Brown KL, Hoskote A. Outcomes, complications, and followup of children
with cardiovascular disease. In: Brogan TV, Lequier L, Lorusso R, MacLaren
G, Peek G, editors. Extracorporeal Life Support: The ELSO Red Book. 5th Edn.
Ann Arbor, MI: ELSO (2017) pp. 395–404.
74. Hamutcu R, Nield TA, Garg M, Keens TG, Platzker ACG. Long-term
pulmonary sequelae in children who were treated with extracorporeal
membrane oxygenation for neonatal respiratory failure. Pediatrics (2004)
114:1292–6. doi: 10.1542/peds.2003-1080-L
75. Zwiers AJ, de Wildt SN, Hop WC, Dorresteijn EM, Gischler SJ, Tibboel D,
et al. Acute kidney injury is a frequent complication in critically ill neonates
receiving extracorporeal membrane oxygenation: a 14-year cohort study.
Crit Care (2013) 17:R151. doi: 10.1186/cc12830
76. Slater MB, Gruneir A, Rochon PA, Howard AW, Koren G, Parshuram CS.
Risk factors of acute kidney injury in critically Ill children. Pediatr Crit Care
Med. (2016) 17:e391–8. doi: 10.1097/PCC.0000000000000859
77. Zwiers AJ, H IJ, van Rosmalen J, Gischler SJ, de Wildt SN, Tibboel D,
et al. CKD and hypertension during long-term follow-up in children and
adolescents previously treated with extracorporeal membrane oxygenation.
Clin J Am Soc Nephrol. (2014) 9:2070–8. doi: 10.2215/CJN.02890314
78. Leeuwen L, Schiller RM, Rietman AB, van Rosmalen J, Wildschut ED,
Houmes RJM, et al. Risk factors of impaired neuropsychologic outcome
in school-aged survivors of neonatal critical illness. Crit Care Med. (2017)
46:401–10. doi: 10.1097/CCM.0000000000002869
79. Schiller RM, Madderom MJ, Reuser JJ, Steiner K, Gischler SJ, Tibboel D,
et al. Neuropsychological follow-up after neonatal ECMO. Pediatrics (2016)
138:e20161313. doi: 10.1542/peds.2016-1313
80. Schiller RM, IJsselstijn H, Madderom MJ, Rietman AB, Smits M, van
Heijst AFJ, et al. Neurobiologic correlates of attention and memory deficits
following critical illness in early life. Crit Care Med. (2017) 45:1742–50.
doi: 10.1097/CCM.0000000000002553
81. Madderom MJ, Schiller RM, Gischler SJ, van Heijst AF, Tibboel D,
Aarsen FK, et al. Growing up after critical illness: verbal, visual-
spatial, and working memory problems in neonatal extracorporeal
membrane oxygenation survivors. Crit Care Med. (2016) 44:1182–90.
doi: 10.1097/CCM.0000000000001626
82. Rourke BP, Bakker DJ, Fisk JL, Strang JD. Child Neuropsychology. An
Introduction to Theory, Research, and Clinical Practice. New York, NY: The
Guilford Press (1983).
83. Schiller RM, Ijsselstijn H, Hoskote A, White T, Verhulst F, van Heijst
AF, et al. Memory deficits following neonatal critical illness: a common
neurodevelopmental pathway. Lancet Child Adolesc Health. (2018) 2:281–
289. doi: 10.1016/S2352-4642(17)30180-3
84. van den Bosch GE, White T, El Marroun H, Simons SH, van der Lugt
A, van der Geest JN, et al. Prematurity, opioid exposure and neonatal
pain: do they affect the developing brain? Neonatology (2015) 108:8–15.
doi: 10.1159/000376566
85. van den Bosch GE, IJsselstijn H, van der Lugt A, Tibboel D, van
Dijk M, White T. Neuroimaging, pain sensitivity, and neuropsychological
functioning in school-age neonatal extracorporeal membrane oxygenation
survivors exposed to opioids and sedatives. Pediatr Crit Care Med. (2015)
16:652–62. doi: 10.1097/PCC.0000000000000474
86. Cooper JM, Gadian DG, Jentschke S, Goldman A, Munoz M, Pitts G, et
al. Neonatal hypoxia, hippocampal atrophy, and memory impairment:
evidence of a causal sequence. Cereb Cortex. (2015) 25:1469–76.
doi: 10.1093/cercor/bht332
87. Schiller RM, van den Bosch GE, Muetzel RL, Smits M, Dudink J,
Tibboel D, et al. Neonatal critical illness and development: white
matter and hippocampus alterations in school-age neonatal extracorporeal
membrane oxygenation survivors. Dev Med Child Neurol. (2017) 59:304–10.
doi: 10.1111/dmcn.13309
88. Dubois J, Dehaene-Lambertz G, Kulikova S, Poupon C, Huppi PS, Hertz-
Pannier L. The early development of brain white matter: a review of imaging
studies in fetuses, newborns and infants. Neuroscience (2014) 276:48–71.
doi: 10.1016/j.neuroscience.2013.12.044
89. Huang SY, Wolahan SM, Mathern GW, Chute DJ, Akhtari M, Nguyen
ST, et al. Improving MRI differentiation of gray and white matter in
epileptogenic lesions based on nonlinear feedback.Magn Reson Med. (2006)
56:776–86. doi: 10.1002/mrm.20987
90. Beaulieu C. The basis of anisotropic water diffusion in the nervous system-a
technical review. NMR Biomed. (2002) 15:435–55. doi: 10.1002/nbm.782
91. Ryerson LM, Guerra GG, Joffe AR, Robertson CM, Alton GY, Dinu IA, et
al. Survival and neurocognitive outcomes after cardiac extracorporeal life
support in children less than 5 years of age: a ten-year cohort. Circ Heart
Fail. (2015) 8:312–21. doi: 10.1161/CIRCHEARTFAILURE.114.001503
92. Lequier L, Joffe AR, Robertson CM, Dinu IA, Wongswadiwat Y, Anton
NR, et al. Two-year survival, mental, and motor outcomes after cardiac
extracorporeal life support at less than five years of age. J Thorac Cardiovasc
Surg. (2008) 136:976–83 e3. doi: 10.1016/j.jtcvs.2008.02.009
93. Garcia Guerra G, Zorzela L, Robertson CM, Alton GY, Joffe AR,
Moez EK, et al. Survival and neurocognitive outcomes in pediatric
extracorporeal-cardiopulmonary resuscitation. Resuscitation (2015) 96:208–
13. doi: 10.1016/j.resuscitation.2015.07.034
94. Wagner K, Risnes I, Berntsen T, Skarbo AB, Ramberg B, Vandvik IH,
et al. Clinical and psychosocial follow-up study of children treated with
extracorporeal membrane oxygenation. Ann Thorac Surg. (2007) 84:1349–
55. doi: 10.1016/j.athoracsur.2007.05.019
95. Hamrick SE, Gremmels DB, Keet CA, Leonard CH, Connell JK, Hawgood S,
et al. Neurodevelopmental outcome of infants supported with extracorporeal
membrane oxygenation after cardiac surgery. Pediatrics (2003) 111(6 Pt
1):e671–5. doi: 10.1542/peds.111.6.e671
96. The Extracorporeal Life Support Organization (ELSO). ELSO




97. Kakat S, O’Callaghan M, Smith L, Hreiche R, Ridout DA, Wray J,
et al. The 1-year follow-up clinic for neonates and children after
respiratory extracorporeal membrane oxygenation support: a 10-year
single institution experience. Pediatr Crit Care Med. (2017) 18:1047–54.
doi: 10.1097/PCC.0000000000001304
98. MacLaren G, Fortenberry J, Tibboel D, Laussen PC. Universal follow-up
after extracorporeal membrane oxygenation: baby steps toward establishing
an international standard of care. Pediatr Crit Care Med. (2017) 18:1070–2.
doi: 10.1097/PCC.0000000000001317
99. Madderom MJ, Reuser JJ, Utens EM, van Rosmalen J, Raets M,
Govaert P, et al. Neurodevelopmental, educational and behavioral
Frontiers in Pediatrics | www.frontiersin.org 12 June 2018 | Volume 6 | Article 177
IJsselstijn et al. Long-Term Follow-Up After ECMO
outcome at 8 years after neonatal ECMO: a nationwide multicenter
study. Intensive Care Med. (2013) 39:1584–93. doi: 10.1007/s00134-013-
2973-1
100. Rathod RH, Farias M, Friedman KG, Graham D, Fulton DR, Newburger
JW, et al. A novel approach to gathering and acting on relevant
clinical information: SCAMPs. Congenit Heart Dis. (2010) 5:343–53.
doi: 10.1111/j.1747-0803.2010.00438.x
101. Rathod RH, Jurgen B, Hamershock RA, Friedman KG, Marshall AC,
Samnaliev M, et al. Impact of standardized clinical assessment and
management plans on resource utilization and costs in children after
the arterial switch operation. Congenit Heart Dis. (2017) 12:768–76.
doi: 10.1111/chd.12508
102. Montoya A, Colom F, Ferrin M. Is psychoeducation for parents and teachers
of children and adolescents with ADHD efficacious? A systematic literature
review. Eur Psychiatry (2011) 26:166–75. doi: 10.1016/j.eurpsy.2010.
10.005
103. Schiller RM, Madderom MJ, van Rosmalen J, Van Heijst A, de Blaauw
I, Utens EM, et al. Working-memory training following neonatal
critical illness: a randomized controlled trial. Crit Care Med. (2018).
doi: 10.1097/CCM.0000000000003151. [Epub ahead of print].
104. McNally H, Bennett CC, Elbourne D, Field DJ, Group UKCET.
United Kingdom collaborative randomized trial of neonatal extracorporeal
membrane oxygenation: follow-up to age 7 years. Pediatrics (2006)
117:e845–54. doi: 10.1542/peds.2005-1167
105. Bennett TD, Spaeder MC, Matos RI, Watson RS, Typpo KV, Khemani RG,
et al. Existing data analysis in pediatric critical care research. Front Pediatr.
(2014) 2:79. doi: 10.3389/fped.2014.00079
106. Peters MJ, Argent A, Festa M, Leteurtre S, Piva J, Thompson A, et al.
The intensive care medicine clinical research agenda in paediatrics.
Intensive Care Med. (2017) 43:1210–24. doi: 10.1007/s00134-017-
4729-9
107. Anderson PJ. Neuropsychological outcomes of children born very preterm.
Semin Fetal Neonatal Med. (2014) 19:90–6. doi: 10.1016/j.siny.2013.11.012
108. Beauchamp MH, Thompson DK, Howard K, Doyle LW, Egan GF,
Inder TE, et al. Preterm infant hippocampal volumes correlate with
later working memory deficits. Brain (2008) 131(Pt 11):2986–94.
doi: 10.1093/brain/awn227
109. Thompson DK, Adamson C, Roberts G, Faggian N, Wood SJ, Warfield
SK, et al. Hippocampal shape variations at term equivalent age in
very preterm infants compared with term controls: perinatal predictors
and functional significance at age 7. Neuroimage (2013) 70:278–87.
doi: 10.1016/j.neuroimage.2012.12.053
110. Uematsu A, Matsui M, Tanaka C, Takahashi T, Noguchi K, Suzuki M, et al.
Developmental trajectories of amygdala and hippocampus from infancy
to early adulthood in healthy individuals. PLoS ONE (2012) 7:e46970.
doi: 10.1371/journal.pone.0046970
111. Fortenberry JD, Lorusso R. The history and development of extracorporeal
support. Neuroimage (2013) 70:278–87.
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
The reviewer RS and handling Editor declared their shared affiliation.
Copyright © 2018 IJsselstijn, Hunfeld, Schiller, Houmes, Hoskote, Tibboel and van
Heijst. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in
other forums is permitted, provided the original author(s) and the copyright owner
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Pediatrics | www.frontiersin.org 13 June 2018 | Volume 6 | Article 177
